Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca's investigational antiplatelet drug AZD6140 has been shown in a phase IIb trial to be more effective at preventing blood clotting than the current industry standard Plavix, co-marketed by Sanofi-Aventis and Bristol-Myers Squibb.
Subscribe to our email newsletter
The studies assessed the safety and tolerability of AZD6140 plus aspirin compared with Plavix plus aspirin in patients with non-ST elevation acute coronary syndromes. These data were presented at the American College of Cardiology annual scientific sessions in Atlanta, Georgia.
AZD6140 is being studied as the first reversible oral adenosine diphosphate (ADP) receptor antagonist for acute coronary syndromes (ACS). It is proposed to selectively inhibit the P2Y12 receptor, a key target receptor for ADP on platelets.
“Oral antiplatelet agents play a key role in the management of acute coronary syndromes, but current therapies do have limitations,” said Dr Robert Storey of the University of Sheffield, UK, and lead investigator in the trials. “The data presented today add to the growing body of knowledge about AZD6140 and its effects on platelet aggregation.”